# Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma

> **NCT07182565** · PHASE1,PHASE2 · RECRUITING · sponsor: **West China Hospital** · enrollment: 84 (estimated)

## Conditions studied

- Gastroesophageal Junction Adenocarcinoma
- Hypofractionated Radiotherapy

## Interventions

- **RADIATION:** hypofractionated radiotherapy
- **DRUG:** PD-1 inhibitor
- **DRUG:** TS-1

## Key facts

- **NCT ID:** NCT07182565
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-18
- **Primary completion:** 2029-08-31
- **Final completion:** 2029-08-31
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07182565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07182565, "Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07182565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*